Squarepoint
FDMT icon

Squarepoint’s 4D Molecular Therapeutics FDMT Stock Holding History

Squarepoint’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-25,576
Closed -$340K – 4600
2026
Q2 		$340K Sell
25,576
-36,937
-59% -$360K ﹤0.01% 3710
2026
Q1 		$582K Sell
62,513
-9,208
-13% -$80.1K ﹤0.01% 3214
2025
Q4 		$538K Buy
71,721
+24,884
+53% +$252K ﹤0.01% 3154
2025
Q3 		$407K Sell
46,837
-6,042
-11% -$36.1K ﹤0.01% 3418
2025
Q2 		$196K Buy
+52,879
New +$186K ﹤0.01% 3984
2024
Q4 		– Sell
-50,320
Closed -$544K – 5157
2024
Q3 		$544K Sell
50,320
-59,721
-54% -$991K ﹤0.01% 3028
2024
Q2 		$2.31M Buy
110,041
+95,422
+653% +$2.39M ﹤0.01% 1945
2024
Q1 		$466K Buy
+14,619
New +$373K ﹤0.01% 3097
2023
Q4 		– Sell
-47,749
Closed -$608K – 4143
2023
Q3 		$608K Buy
47,749
+33,056
+225% +$553K ﹤0.01% 2646
2023
Q2 		$266K Sell
14,693
-46,665
-76% -$859K ﹤0.01% 3039
2023
Q1 		$1.05M Sell
61,358
-768
-1% -$14.9K ﹤0.01% 1857
2022
Q4 		$1.38M Buy
+62,126
New +$960K 0.01% 1603

Other funds holding FDMT

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

Squarepoint's FDMT Position: Q3 2026 in Review

Squarepoint sold out of 4D Molecular Therapeutics (FDMT) in Q3 2026, closing a stake of 25,576 shares — an estimated $340K sold.

Squarepoint first reported a position in FDMT in Q4 2022 and held it in 12 quarters. The position peaked at $2.31M in Q2 2024. 82 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

  • Squarepoint reported no remaining 4D Molecular Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Squarepoint sold 25,576 4D Molecular Therapeutics shares in Q3 2026, an estimated $340K.
  • Squarepoint first reported a position in 4D Molecular Therapeutics in Q4 2022 and held it in 12 quarters.
  • Squarepoint's 4D Molecular Therapeutics position peaked at $2.31M in Q2 2024.
  • 82 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.